文献速递胸部肿瘤骨软组织肉瘤与黑色素瘤泌尿男性生殖肿瘤

Pegilodecakin联合抗PD-1抗体治疗晚期实体瘤的1b期IVY研究

Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial.
PubMed 文献 · Lancet Oncol · 2019-09-25

这项多中心、多队列、开放标签1b期试验评估了Pegilodecakin联合帕博利珠单抗或纳武利尤单抗治疗晚期实体瘤的安全性和活性。111例患者中,3-4级治疗相关不良事件发生率为66%,客观缓解率在非小细胞肺癌为43%、黑色素瘤为10%、肾细胞癌为40%。联合方案毒性可控并显示初步抗肿瘤活性,可能为经治肾细胞癌和非小细胞肺癌提供新治疗机会。

要点

  • Pegilodecakin联合抗PD-1抗体在经治晚期实体瘤中3-4级不良事件发生率为66%。
  • 客观缓解率:非小细胞肺癌43%、肾细胞癌40%、黑色素瘤10%。
  • 联合方案毒性可控,或为经治肾细胞癌和非小细胞肺癌提供新选择。

核心结论

  • Pegilodecakin联合抗PD-1单抗在经治晚期实体瘤中毒性可控并显示初步抗肿瘤活性。

研究设计与样本

  • 多中心、多队列、开放标签1b期试验(IVY),在美国12家癌症研究中心开展。
  • 2015年2月13日至2017年9月12日入组111例晚期实体瘤患者,53例接受Pegilodecakin联合帕博利珠单抗,58例联合纳武利尤单抗。
  • 主要终点为安全性和药代动力学,次要终点包括免疫相关疗效标准的客观缓解。

主要发现

  • 111例中103例(93%)发生至少1例治疗相关不良事件,73例(66%)发生3-4级事件。
  • 3-4级事件最常见为贫血(帕博利珠单抗组23%,纳武利尤单抗组28%)、血小板减少(26%和21%)、乏力(21%和10%)和高甘油三酯血症(6%和14%)。
  • 可评估患者中客观缓解:非小细胞肺癌12/28(43%)、黑色素瘤3/31(10%)、肾细胞癌14/35(40%)。
  • 无归因于研究治疗的致死性不良事件。

临床怎么用

  • 联合方案在经治肾细胞癌和非小细胞肺癌中显示初步活性,或可成为潜在治疗选择。
  • 治疗期间需重点监测贫血、血小板减少、乏力及高甘油三酯血症等3-4级不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: IL-10 has anti-inflammatory and CD8+ T-cell stimulating activities. Pegilodecakin (pegylated IL-10) is a first-in-class, long-acting IL-10 receptor agonist that induces oligoclonal T-cell expansion and has single-agent activity in advanced solid tumours. We assessed the safety and activity of pegilodecakin with anti-PD-1 monoclonal antibody inhibitors in patients with advanced solid tumours. METHODS: We did a multicentre, multicohort, open-label, phase 1b trial (IVY) at 12 cancer research centres in the USA. Patients were assigned sequentially into cohorts. Here, we report on all enrolled patients from two cohorts treated with pegilodecakin combined with anti-PD-1 inhibitors. Eligible patients were aged at least 18 years with histologically or cytologically confirmed advanced malignant solid tumours refractory to previous therapies, and an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients with uncontrolled infectious diseases were excluded. Pegilodecakin was provided in single-use 3 mL vials and was self-administered subcutaneously by injection at home at 10 μg/kg or 20 μg/kg once per day in combination with pembrolizumab (2 mg/kg every 3 weeks or 200 mg every 3 weeks) or nivolumab (3 mg/kg every 2 weeks or 240 mg every 2 weeks or 480 mg every 4 weeks at the approved dosing), both of which were given intravenously at the study site. Patients received pembrolizumab or nivolumab with pegilodecakin until disease progression, toxicity necessitating treatment discontinuation, patient withdrawal of consent, or study end. The primary endpoints were safety and tolerability, assessed in all patients enrolled in the study who received any amount of study medication including at least one dose of pegilodecakin, and pharmacokinetics (previously published). Secondary endpoints included objective response by immune-related response criteria in all patients who were treated and had evaluable measurements. The study is active but no longer recruiting, and is registered with ClinicalTrials.gov, NCT02009449. FINDINGS: Between Feb 13, 2015, and Sept 12, 2017, 111 patients were enrolled in the two cohorts. 53 received pegilodecakin plus pembrolizumab, and 58 received pegilodecakin plus nivolumab. 34 (31%) of 111 patients had non-small-cell lung cancer, 37 (33%) had melanoma, and 38 (34%) had renal cell carcinoma; one (<1%) patient had triple-negative breast cancer and one (<1%) had bladder cancer. Data cutoff was July 1, 2018. Median follow-up was 26·9 months (IQR 22·3-31·5) for patients with non-small-cell lung cancer, 33·0 months (29·2-35·1) for those with melanoma, and 22·7 months (20·9-27·0) for those with renal cell carcinoma. At least one treatment-related adverse event occurred in 103 (93%) of 111 patients. Grade 3 or 4 events occurred in 73 (66%) of 111 patients (35 [66%] of 53 in the pembrolizumab group and 38 [66%] of 58 in the nivolumab group), the most common of which were anaemia (12 [23%] in the pembrolizumab group and 16 [28%] in the nivolumab group), thrombocytopenia (14 [26%] in the pembrolizumab group and 12 [21%] in the nivolumab group), fatigue (11 [21%] in the pembrolizumab group and 6 [10%] in the nivolumab group) and hypertriglyceridaemia (three [6%] in the pembrolizumab group and eight [14%] in the nivolumab group). There were no fatal adverse events determined to be related to the study treatments. Of the patients evaluable for response, objective responses were 12 (43%) of 28 (non-small-cell lung cancer), three (10%) of 31 (melanoma), and 14 (40%) of 35 (renal cell carcinoma). INTERPRETATION: In this patient population, pegilodecakin with anti-PD-1 monoclonal antibodies had a manageable toxicity profile and preliminary antitumour activity. Pegilodecakin with pembrolizumab or nivolumab could provide a new therapeutic opportunity for previously treated patients with renal cell carcinoma and non-small-cell carcinoma. FUNDING: ARMO BioSciences, a wholly owned subsidiary of Eli Lilly and Company.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Naing A, Wong DJ, Infante JR, et al. Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial. Lancet Oncol. 2019. PMID: 31563517. doi:10.1016/S1470-2045(19)30514-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。